tiprankstipranks
Trending News
More News >
Privia Health Group (PRVA)
NASDAQ:PRVA
US Market

Privia Health Group (PRVA) AI Stock Analysis

Compare
210 Followers

Top Page

PRVA

Privia Health Group

(NASDAQ:PRVA)

Select Model
Select Model
Select Model
Outperform 71 (OpenAI - 4o)
Rating:71Outperform
Price Target:
$26.00
▲(4.75% Upside)
Privia Health Group's strong financial performance and positive earnings call are the primary drivers of its stock score. However, the high P/E ratio suggests overvaluation, and technical indicators point to a neutral to slightly bearish trend. The strategic acquisition supports future growth, but the loss of a board member is a minor concern.
Positive Factors
Revenue Growth
Strong revenue growth indicates effective market expansion and increased adoption of Privia's services, supporting long-term business sustainability.
Strategic Acquisition
The acquisition enhances Privia's market positioning and operational capabilities, expanding its value-based care network and potential synergies.
Cash Position
A strong cash position with no debt provides financial flexibility for growth investments and buffers against economic uncertainties.
Negative Factors
EBIT Margin Fluctuations
Fluctuating EBIT margins can impact profitability and indicate potential inefficiencies in cost management, affecting long-term financial health.
Capitation Model Challenges
Challenges in the capitation model could limit profitability and growth in Medicare Advantage, impacting future revenue streams.
Free Cash Flow Volatility
Volatility in free cash flow growth can lead to unpredictability in cash availability, affecting the company's ability to fund operations and growth.

Privia Health Group (PRVA) vs. SPDR S&P 500 ETF (SPY)

Privia Health Group Business Overview & Revenue Model

Company DescriptionPrivia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. was a former subsidiary of Brighton Health Group Holdings, LLC.
How the Company Makes MoneyPrivia Health generates revenue through a multi-faceted model that primarily includes service fees from healthcare providers who utilize its technology and management services. Key revenue streams consist of subscription fees for its platform, performance-based incentives tied to value-based care initiatives, and fees for ancillary services such as care coordination and patient engagement tools. Strategic partnerships with payers and healthcare organizations further bolster its earnings by facilitating broader access to its services and enhancing its value proposition in the healthcare market.

Privia Health Group Earnings Call Summary

Earnings Call Date:Nov 06, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Mar 03, 2026
Earnings Call Sentiment Positive
Privia Health's third-quarter earnings call highlighted strong financial performance, growth in attributed lives, and successful expansion plans. Despite challenges in the Medicare Advantage capitation model and conservative guidance for Q4, the company's overall results and strategic acquisitions position it well for future success.
Q3-2025 Updates
Positive Updates
Strong Financial Performance
Privia Health's practice collections increased 27.1% year-over-year, reaching $940.4 million in Q3. Adjusted EBITDA rose 61.6% to $38.2 million, with an EBITDA margin of 30.5%.
Medicare Shared Savings Program Success
The Medicare Shared Savings Program demonstrated an aggregate savings rate of 9.4%, up from 8.2% in 2023, with total shared savings of $234.1 million, a 32.6% increase from the previous year.
Expansion and Growth
Privia Health's implemented provider growth was 13.1% year-over-year, and attributed lives increased by nearly 13%. The acquisition of an ACO business from Evolent Health will add over 120,000 value-based care attributed lives.
Cash Position and Financial Flexibility
Privia Health reported pro forma cash of $409.9 million with no debt, forecasting at least $410 million in cash by year-end, positioning the company for further growth opportunities.
Negative Updates
Capitation Model Challenges
Despite some favorable retroactive adjustments, the company remains cautious about headwinds in the Medicare Advantage capitation model.
Conservative Q4 Guidance
The guidance for Q4 shows limited profitability growth with low single-digit year-over-year growth and some margin compression expected.
Company Guidance
During the Privia Health Third Quarter 2025 Results Conference Call, the company reported robust performance indicators, highlighting a 27.1% year-over-year increase in practice collections and a 61.6% rise in adjusted EBITDA, with the EBITDA margin expanding by 720 basis points to 30.5%. The company also noted a 13.1% growth in implemented providers and a 12.8% increase in value-based attribution. Privia Health's total attributed lives grew nearly 13%, driven by new provider growth and entry into new markets like Arizona. The acquisition of an accountable care organization (ACO) business from Evolent Health for $100 million, plus an earn-out of up to $13 million, is expected to expand Privia's attributed lives to over 1.5 million. Despite these significant investments, the company maintains a strong cash position with $410 million anticipated by year-end. Based on this performance, Privia Health raised its 2025 outlook above previous ranges, expecting practice collections growth of 17.1%, care margin growth of 13.2%, and adjusted EBITDA growth of 32%, with over 80% of full-year EBITDA expected to convert to free cash flow.

Privia Health Group Financial Statement Overview

Summary
Privia Health Group exhibits strong financial performance with significant revenue growth, efficient cost management, and a robust equity base. However, fluctuations in EBIT margins and free cash flow growth warrant attention.
Income Statement
85
Very Positive
Privia Health Group has shown impressive revenue growth over the years, with the latest figure reaching $1.74 billion, a significant increase from previous years. The gross profit margin is robust, indicating efficient cost management. Despite a slight decline in EBIT and EBITDA margins in the latest year, the company maintains a positive net profit margin, showcasing profitability. However, the fluctuation in EBIT margins could be a point of concern.
Balance Sheet
80
Positive
The company exhibits a strong equity base, with a healthy debt-to-equity ratio indicating low leverage, which is favorable for stability. The return on equity has improved over the years, reflecting effective utilization of shareholder funds. A high equity ratio further underscores financial robustness, though continuous monitoring of debt levels is advised.
Cash Flow
78
Positive
Privia Health Group has demonstrated consistent growth in operating cash flow, which is a positive indicator of cash-generating efficiency. The operating cash flow to net income ratio is strong, suggesting effective conversion of earnings into cash. However, the free cash flow growth rate has experienced some volatility, signaling potential fluctuations in cash availability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.04B1.74B1.66B1.36B966.22M817.08M
Gross Profit202.39M176.85M161.50M134.78M63.66M82.58M
EBITDA41.97M24.25M27.18M-14.55M-214.97M27.22M
Net Income18.17M14.38M23.08M-8.59M-188.23M31.24M
Balance Sheet
Total Assets1.35B1.14B999.90M792.81M686.37M328.97M
Cash, Cash Equivalents and Short-Term Investments441.35M491.15M389.51M347.99M320.58M84.63M
Total Debt6.24M5.59M8.29M11.50M46.50M33.66M
Total Liabilities588.23M452.34M392.51M273.76M236.19M185.32M
Stockholders Equity709.12M635.18M561.44M499.09M426.87M146.75M
Cash Flow
Free Cash Flow109.50M104.26M80.67M47.09M54.51M38.51M
Operating Cash Flow110.70M109.28M80.78M47.20M55.06M38.89M
Investing Cash Flow-96.52M-10.32M-48.01M-104.00K-32.77M-380.00K
Financing Cash Flow5.18M2.68M8.74M-19.68M213.66M-767.00K

Privia Health Group Technical Analysis

Technical Analysis Sentiment
Positive
Last Price24.82
Price Trends
50DMA
24.43
Positive
100DMA
23.09
Positive
200DMA
23.05
Positive
Market Momentum
MACD
<0.01
Negative
RSI
58.59
Neutral
STOCH
55.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRVA, the sentiment is Positive. The current price of 24.82 is above the 20-day moving average (MA) of 23.82, above the 50-day MA of 24.43, and above the 200-day MA of 23.05, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.59 is Neutral, neither overbought nor oversold. The STOCH value of 55.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRVA.

Privia Health Group Risk Analysis

Privia Health Group disclosed 55 risk factors in its most recent earnings report. Privia Health Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Privia Health Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
$2.93B167.892.74%19.01%38.68%
66
Neutral
$718.56M35.505.87%0.51%3.68%5.62%
59
Neutral
$2.34B-103.210.42%2.97%-21.26%-119.34%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
$433.01M-13.63%-16.65%-71.92%
47
Neutral
$1.36B-15.42%-2.37%77.85%
42
Neutral
$396.10M-1.05-47.69%-5.30%46.01%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PRVA
Privia Health Group
24.91
3.95
18.85%
HSTM
HealthStream
24.17
-8.07
-25.03%
PINC
Premier
28.26
7.09
33.49%
EVH
Evolent Health
4.12
-7.26
-63.80%
TDOC
Teladoc
7.55
-2.87
-27.54%
DH
Definitive Healthcare Corp
2.31
-2.18
-48.55%

Privia Health Group Corporate Events

M&A TransactionsBusiness Operations and Strategy
Privia Health Finalizes Acquisition of ACO Business
Positive
Dec 8, 2025

Privia Health Group, Inc. announced the acquisition of an Accountable Care Organization business from Evolent Health, Inc. The transaction, which was initially announced on September 23, 2025, was finalized on December 5, 2025, potentially enhancing Privia’s market positioning and operational capabilities.

Executive/Board Changes
Privia Health Mourns Loss of Board Member
Negative
Oct 28, 2025

On October 24, 2025, Patricia Maryland, a member of the Board of Directors and Chair of the Compliance Committee at Privia Health Group, passed away. The company expressed sadness at her passing and gratitude for her significant contributions over the past five years.

M&A TransactionsBusiness Operations and Strategy
Privia Health Acquires ACO Business for $100 Million
Positive
Sep 23, 2025

On September 23, 2025, Privia Health Group announced its agreement to acquire an Accountable Care Organization business from Evolent Health for $100 million, with an additional $13 million contingent on performance. This acquisition, expected to close in the fourth quarter of 2025, will expand Privia Health’s value-based care arrangements to approximately 1.5 million attributed lives, enhancing its national network and offering synergy opportunities for participating providers.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 09, 2025